/

Sociétés

Me

Non vérifié

Memo Therapeutics AG

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinancePublicité/Marketing/Médias/Communication

3 communiqués de presse

Voir tous les communiqués de presse

08/02/2026

Biotechnologie

Publicité/Marketing/Médias/Communication

Finance

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

Source

Memo Therapeutics AG

Émetteur

1.00

0

06/11/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Re-source Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting

Source

Memo Therapeutics AG

Émetteur

1.00

0

24/07/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Source

Memo Therapeutics AG

Émetteur

1.00

0

Followers

0

Compatibilité

0